Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
about
Applications of CYP450 testing in the clinical settingIn vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneCYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markersEffects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys.Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry MethodRepeated administration of berberine inhibits cytochromes P450 in humansCytochromes P450: a structure-based summary of biotransformations using representative substrates.Pharmacokinetic evaluation of losartan.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.Clinically significant CYP2C inhibition by noscapine but not by glucosamine.Paeoniae Radix, a traditional Chinese medicine, and CYP2C9 activity.Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia.Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro.Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.SuperDRUG2: a one stop resource for approved/marketed drugs.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase.In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS.Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.
P2860
Q24621760-6F35A461-5CAF-45E9-AA98-19294A6F9A4CQ33777963-FAE49BD2-71F9-4DF3-9292-AABF3DD74E83Q33984240-A1935550-8BCD-4F2F-A20B-21F093890228Q35594567-84D00A8A-8675-47E4-B791-3AA4C0E0DBDAQ35753607-E3EB0F15-30DB-467B-A550-37C2A167643FQ36125465-6C0C6604-0ABD-4B54-9664-15F4B0BD981EQ36460560-767DDA7F-1114-406F-8C4E-292D93620A13Q36490986-52D2F8A8-7B46-4AC7-9EDA-A473ADE04D60Q36508913-0735B5CC-27B5-4A34-B389-011A7651AC88Q36983633-A29FDD56-0E91-4BD9-8CCB-82635D6847D1Q37079954-4CB8BCD7-6D82-4560-AE66-5C6A8FA3C866Q37854746-AB855CF8-0E8C-4965-9A14-C91320B7C58BQ37955160-7B7E04AE-421D-498F-A7B3-24FC0409E35BQ38643436-08D9E24A-31B8-4AD4-A104-42C8B76F17BCQ39232150-9B417590-254A-4080-9F71-9C97FFC1B04AQ39631863-B85B6CDC-5C71-4F0C-AB9C-AB2B630DD187Q42780160-ED18C997-783F-4884-B8F5-A5CE900FD104Q42953232-88090220-5E5F-4589-9462-6E7ECA91E731Q44039719-B804A984-EC6F-4E20-8A96-351E30346266Q44273797-EE2E62E9-61EC-4C93-BFA7-872C75592B55Q44405606-128BBA5D-4C5C-462B-B34D-0E55887EE528Q44438917-BE4E5ECC-A79B-4285-8944-494F1437FF49Q44487379-A1C9B6AA-596C-4B28-912C-1B46A33D3DD2Q44852656-AF780F6A-19D4-4D9D-9133-3ABEF6F03741Q45058224-0E31EFCC-2573-4E7A-9C71-69FB857CE73AQ45213491-B089DC7A-78CF-45B6-9DFB-6F8F405C9377Q45928715-A40F0D3B-50D8-42D9-A820-93571361477BQ46221248-D9DF0C44-FE2B-4592-BA15-732615840B05Q46762942-17CAA560-3B37-45D4-B49D-69D4C2BA2B6FQ46918393-321B2AB4-D507-4D86-A8C0-BE951AC60616Q46975102-49DA939E-F937-4A31-AE2E-74B7265D021CQ47142191-DCF666F7-75CF-4308-9EF8-35B1F81017A0Q47570862-41AE39EA-BAC7-4261-8B19-5EFFE5B7C873Q47622129-48D0708C-5DCE-48B4-8B5C-027784694D88Q47744170-406929CF-E3E0-40F7-BAC3-2377DCC60319Q48336005-E0750D82-6EFB-4076-814B-3289E293BD77Q52761132-A23CFC00-9DCC-48B9-AD57-B64152AA7B1EQ52903732-8CFFE197-2811-4257-A574-CEF408B17B1DQ53515317-2B2512C5-72E7-4EAC-84ED-90F6FE3D5277Q54172975-7CEC2FE5-C3EF-47FA-B3BE-7ED204BE94FA
P2860
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@en
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@nl
type
label
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@en
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@nl
prefLabel
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@en
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@nl
P2093
P50
P356
P1476
Pharmacokinetics of losartan a ...... lation to the CYP2C9 genotype.
@en
P2093
Adrián Llerena
Cecilia Forslund-Bergengren
Folke Sjöqvist
Gunnel Tybring
Marja-Liisa Dahl
P356
10.1067/MCP.2002.121216
P407
P577
2002-01-01T00:00:00Z